Medicamen Biotech Net Profit Surges 95% YoY to ₹4.1 Crore in Q2 FY27

Key numbers

PE TTM	36.54Sector PE 43.78
Market Cap	₹395.73 CrPharmaceuticals
RSI	46.89Neutral Zone
Promoter Holding	42.57%Up 2.11% QoQ

Key highlights

• Revenue from operations increased 16.1% year-on-year to ₹54.8 crore in Q2 FY27
• Net profit grew by 127.8% on a sequential basis, rising from ₹1.8 crore in Q1 FY27
• Operating margins expanded to 9.3%, compared to 5.7% in the same quarter last year
• Profit before tax stood at ₹5.1 crore for the quarter ended September 30, 2026
• The company raised ₹26.50 crore through a preferential allotment on October 23, 2026

Operating Performance and Margin Expansion

Medicamen Biotech recorded a 16.1% year-on-year increase in revenue from operations, reaching ₹54.8 crore for the second quarter of FY27 compared to ₹47.2 crore in the corresponding period last year. The pharmaceutical firm also demonstrated significant sequential growth, with revenues climbing 14.4% from ₹47.9 crore in Q1 FY27. This topline expansion was accompanied by a notable recovery in operating efficiency, as the operating margin improved to 9.3% from 5.3% in the preceding quarter.

The bottom-line performance reflected these gains, with net profit surging 95.2% year-on-year to ₹4.1 crore, highlighting improved cost management across its pharmaceutical operations.

Strategic Capital Raise and Global Pipeline

• The company successfully concluded a preferential allotment of 5,00,000 equity shares at ₹530 per share on October 23, 2026.
• Proceeds of ₹26.50 crore from the capital raise are earmarked for regulatory filings and expansion initiatives through mid-2027.
• A development pipeline consisting of 50 SKUs across oncology, diabetes, and cardiology is currently funded for regulated global markets.
• Consolidated financial results include operations from subsidiaries Opal Pharmaceuticals Pty Ltd and Medicamen Life Sciences Private Limited.
• The company reported an unmodified audit opinion for both standalone and consolidated financial statements for the period.

Compliance and Subsidiary Performance

The Board of Directors addressed regulatory matters during the meeting, noting fines totaling ₹40,120 imposed by both the BSE and NSE. These penalties related to non-compliance with SEBI regulations concerning the composition of the Nomination and Remuneration Committee for the quarter ended June 30, 2026. Management has since apprised the board of corrective measures implemented to ensure strict adherence to SEBI Listing Obligations and Disclosure Requirements going forward.

Financially, the company maintains a mid-range performance profile with a durability score of 75 and a trailing twelve-month price-to-earnings ratio of 36.54, which remains positioned below the sector average of 43.78.

What to watch next

• Deployment of ₹103.62 crore in preferential issue proceeds for regulatory filings by June 30, 2027
• Approval and launch milestones for the 50 SKU oncology and cardiology pipeline
• Third-quarter FY27 financial results announcement expected in February 2027

“the reports of Auditors are with unmodified opinion with respect to the Unaudited Financial Results of the Company for the quarter ended September 30, 2026.”

Medicamen Biotech · financial snapshot

Share price	₹281.4
Market capitalisation	₹395.73 Cr
Revenue (annual)	₹197.77 Cr
Net profit (annual)	₹9.64 Cr
Revenue (latest quarter)	₹47.90 Cr-21.02% vs previous quarter
Net profit (latest quarter)	₹2.12 Cr-45.08% vs previous quarter
P/E (TTM)	36.54×Sector 43.78×
Promoter holding	42.57%+2.11% QoQ
FII holding	4.35%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.